KEZAR LIFE SCIENCES INC (KZR)
US49372L1008 - Common Stock
KZR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. While KZR seems to be doing ok healthwise, there are quite some concerns on its profitability. KZR is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year KZR has reported negative net income.
KZR had a negative operating cash flow in the past year.
KZR had negative earnings in each of the past 5 years.
KZR had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -46.05%, KZR perfoms like the industry average, outperforming 51.16% of the companies in the same industry.
The Return On Equity of KZR (-54.31%) is better than 64.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.05% | ||
| ROE | -54.31% | ||
| ROIC | N/A |
ROA(3y)-31.3%
ROA(5y)-32.12%
ROE(3y)-35.78%
ROE(5y)-36.39%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for KZR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
KZR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, KZR has less shares outstanding
Compared to 5 years ago, KZR has less shares outstanding
KZR has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 6.97 indicates that KZR is not in any danger for bankruptcy at the moment.
The Altman-Z score of KZR (6.97) is better than 81.82% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that KZR is not too dependend on debt financing.
KZR has a worse Debt to Equity ratio (0.05) than 62.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.97 |
ROIC/WACCN/A
WACC10.49%
2.3 Liquidity
KZR has a Current Ratio of 11.66. This indicates that KZR is financially healthy and has no problem in meeting its short term obligations.
KZR has a Current ratio of 11.66. This is amongst the best in the industry. KZR outperforms 85.38% of its industry peers.
A Quick Ratio of 11.66 indicates that KZR has no problem at all paying its short term obligations.
KZR has a Quick ratio of 11.66. This is amongst the best in the industry. KZR outperforms 85.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.66 | ||
| Quick Ratio | 11.66 |
3. Growth
3.1 Past
KZR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -461.74%.
EPS 1Y (TTM)-461.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-694.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 9.84% on average over the next years. This is quite good.
The Revenue is expected to grow by 63.57% on average over the next years. This is a very strong growth
EPS Next Y-778.68%
EPS Next 2Y-173.81%
EPS Next 3Y-97.98%
EPS Next 5Y9.84%
Revenue Next Year-64.29%
Revenue Next 2Y-22.84%
Revenue Next 3Y-25.99%
Revenue Next 5Y63.57%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for KZR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KZR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
KZR's earnings are expected to decrease with -97.98% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-173.81%
EPS Next 3Y-97.98%
5. Dividend
5.1 Amount
No dividends for KZR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
KEZAR LIFE SCIENCES INC
NASDAQ:KZR (11/15/2024, 8:22:20 PM)
After market: 7.5 +0.04 (+0.54%)7.46
-0.06 (-0.8%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap544.28M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.05% | ||
| ROE | -54.31% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 11.66 | ||
| Quick Ratio | 11.66 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-461.74%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-778.68%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y